<DOC>
	<DOCNO>NCT00644475</DOCNO>
	<brief_summary>BACKGROUND The effect ACE-inhibitors fibrinolysis well document . Experimental clinical study show ACE inhibitor induce reduction plasma PAI-1 level many cardiovascular disease , like hypertension , coronary heart disease , heart failure . Their effect t-PA controversial , due fact t-PA exist several form , include free bound PAI-1 . Indeed increase t-PA activity observe human seem related bradykinin increase know stimulate endothelial t-PA synthesis . These favourable effect fibrinolysis could relate Angiotensin II reduction bradykinin increase also improvement insulin sensitivity , insulin suggest one main regulator fibrinolytic activity . To date conflicting result report effect ARBs fibrinolysis . Some study report small improvement , others significant effect . These conflict result may due possible methodological bias possible pathophysiological explanation might receptor subtypes AT1 mediate effect Angiotensin-II endothelial PAI-1 expression , i.e . AT4 receptor , AT1 receptor blockade important increase Angiotensin-II , also catabolites include Angiotensin IV . The dissimilar effect ACE Is ARBs may also depend different action RAS different effect insulin sensitivity : ACE-Is improve insulin sensitivity , majority ARBs report neutral effect . Moreover , unlike ACE-Is , ARBs affect metabolism bradykinin , know stimulate t-PA synthesis release . AIM OF THE STUDY The aim study verify effect imidapril compare candesartan insulin sensitivity , evaluate euglycemic hyperinsulinemic clamp , fibrinolysis , evaluate plasma PAI-1 t-PA activity , mild moderate hypertensive patient .</brief_summary>
	<brief_title>Imidapril Candesartan Fibrinolysis Insulin-Sensitivity Patients With Mild Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Imidapril</mesh_term>
	<criteria>Age 1865 year DBP ≥ 90 &lt; 110 mmHg SBP ≥ 140 &lt; 180 mmHg Normal Body Mass Index ( BMI ) ( ≤ 25 Kg/m2 ) Normal kidney function ( Creatinine Clearance &gt; 80 ml/min ) Normocholesterolemia ( TC &lt; 250 mg/dl ) At least one follow risk factor : age ( M &gt; 55 year ) smoke family history premature CV disease echocardiographic LVH carotid wall thickening ( IMT &gt; 0.9 mm ) ankle/brachial BP &lt; 0.9 Secondary hypertension Overweight obese state ( BMI ≥ 25 Kg/m2 ) Suspected history allergy ARBs , ACEs Malignancy Renal , hepatic , endocrine , gastrointestinal disease Women pregnant lactate Women childbearing potential Heart failure AMI and/or stroke previous 6 month CHD Diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Fibrinolysis</keyword>
</DOC>